rDEN3Δ30

rDEN3Δ30 is a live attenuated monovalent dengue virus vaccine candidate derived from dengue virus serotype 3 (DENV-3) by introducing a 30-nucleotide deletion in the 3′ untranslated region (UTR) of the viral genome. This genetic modification attenuates the virus while preserving its immunogenicity. The vaccine is designed to induce protective immunity against DENV-3 infection and has been evaluated both as a monovalent vaccine and as part of tetravalent formulations for broader dengue protection. Clinical studies have shown that rDEN3Δ30 is highly infectious and immunogenic in humans, inducing robust neutralizing antibody responses with mild to moderate clinical symptoms such as rash but without significant fever or severe adverse events. The primary developer is the National Institute of Allergy & Infectious Diseases (NIAID)[1][4][5][8].

Other names

DENV-3 Δ30recombinant dengue virus type 3 with 30-nucleotide deletionrDEN3-Δ30